Eagle Pharmaceuticals, Inc. Policy for Stockholder Communications with the Board of Directors

Investors Menu

Eagle Pharmaceuticals, Inc.

Process For
Stockholder Communications With The Board OfDirectors

Stockholders of Eagle Pharmaceuticals, Inc. (“Eagle”) wishing to communicate with Eagle’s Board of Directors (the“Board”) or an individual director may send a written communication to the Board or such director c/o Eagle Pharmaceuticals, Inc., 50 Tice Blvd., Suite 315, Woodcliff Lake, NJ 07677, Attn: Secretary. Each communication must set forth:

  • the name and address of the Eagle stockholder on whose behalf the communication is sent; and
  • the number of Eagle shares that are owned beneficially by such stockholder as of the date of the communication.

Each communication will be reviewed by Eagle’s Secretary to determine whether it is appropriate for presentation to the Board or such director. Examples of inappropriate communications include advertisements, solicitations or hostile communications.

Communications determined by the Secretary to be appropriate for presentation to the Board or such director will be submitted to the Board or such director on a periodic basis.

Investor Contact

In-Site
Communications, Inc.
Lisa M. Wilson,
212-452-2793

For all other media inquiries, please contact us.